中東およびアフリカの感染症治療薬市場予測 2030年 - 地域別分析 - 薬剤クラス別（抗ウイルス、抗菌、抗真菌、その他）、適応症別（HIV、肝炎、結核、インフルエンザ、HPV、その他）、投与経路別（経口、非経口、局所、その他）、流通チャネル別（病院薬局、小売薬局、その他）
感染症の蔓延の増加が中東およびアフリカの感染症治療薬市場を活性化
感染症は、ウイルス、寄生虫、細菌、真菌、有毒物質、その他の感染性病原体によって引き起こされます。HIVは世界中で大きな公衆衛生問題となっています。国連エイズ合同計画（UNAIDS）によると、2020年に約3,770万人がHIVに感染していました。このうち、3,600万人が成人、170万人が0～14歳の子供でした。また、半数以上（53％）が少女と女性でした。さらに、2020年には世界中で150万人の新たなHIV感染者が報告されました。同様に、肝炎はウイルス感染によって引き起こされる肝臓の感染症です。肝炎ウイルスの主な種類は、A、B、C、D、Eです。世界保健機関（WHO）によると、世界中で約5,800万人が慢性C型肝炎ウイルス感染症に苦しんでおり、毎年約150万人の新規感染が発生しています。
WHOによると、結核（TB）は世界で13番目に多い死因であり、COVID-19に次ぐ2番目に多い感染症です。2020年には、150万人が結核で亡くなりました（HIVに感染した214,000人を含む）。さらに、2020年には世界中で1,000万人が結核に罹患し、そのうち110万人が子供、330万人が女性、560万人が男性でした。さらに、院内感染や医療関連感染（HAI）は罹患率と死亡率が高く、医療システムへの支出も毎年莫大です。したがって、世界中で感染症の蔓延が進んでいることが、感染症治療薬市場の成長を牽引しています。
中東およびアフリカの感染症治療薬市場の概要
中東およびアフリカの感染症治療薬市場には、UAE、サウジアラビア、南アフリカ、その他の中東およびアフリカの国レベルの分析が含まれています。市場の成長は、慢性ウイルス性疾患の蔓延の増加と、地域全体での研究の増加に起因しています。さらに、高度な医療施設の出現は、予測期間中に市場の成長を促進する可能性があります。サウジアラビアは、巨大な人口基盤と感染症の蔓延の増加により、中東およびアフリカで最も急速に成長している地域の1つです。サウジアラビアの結核は、移民労働者と巡礼者を通じて広がっています。ワールド・データ・アトラスによると、サウジアラビアの結核発症率は、2002年の10万人あたり17件から2021年には10万人あたり8件に徐々に減少している。さらに、尿路、血流、呼吸器の院内感染である肺炎桿菌は、サウジアラビアでは制御が非常に困難である。WHOによると、インフルエンザと肺炎による死亡者は、同国の全死亡者の4.58%に達した。増加するインフルエンザ症例に対処するため、サウジアラビアの公衆衛生研究所は、サウジアラビアの国立インフルエンザセンターとして認定されるためのWHOのすべての要件を満たした。センターは、感染症の迅速な検出と監視において重要な役割を果たしている。NIAIDは、MERS-CoVを含む、この地域の感染性ウイルス性疾患の研究に大きく関与している。新たに特定されたコロナウイルスであるMERS-CoVは、この地域の少なくとも9か国に広がっている。 NIAID は、この地域の感染性ウイルス性疾患の研究に大きく関与しています。同様に、この地域での製品の発売が増加しており、患者の生活の質にプラスの影響を与えています。したがって、ウイルス性疾患と製品の発売の増加により、この国の感染症治療薬の成長が促進されると予想されます。
中東およびアフリカの感染症治療薬市場の収益と 2030 年までの予測 (百万米ドル)
中東およびアフリカの感染症治療薬市場のセグメンテーション
中東およびアフリカの感染症治療薬市場は、薬物クラス、適応症、投与経路、流通チャネル、および国に分類されています。
薬物クラスに基づいて、中東およびアフリカの感染症治療薬市場は、抗ウイルス、抗菌、抗真菌、その他に分類されています。 2022年には、抗ウイルスセグメントが最大の市場シェアを占めました。
適応症別に見ると、中東およびアフリカの感染症治療薬市場は、HIV、肝炎、結核、インフルエンザ、HPV、その他に分類されています。2022年には、HIVが最大の市場シェアを占めました。
投与経路別に見ると、中東およびアフリカの感染症治療薬市場は、経口、非経口、局所、その他に分類されています。2022年には、経口セグメントが最大の市場シェアを占めました。
流通チャネル別に見ると、中東およびアフリカの感染症治療薬市場は、病院薬局、小売薬局、その他に分類されています。2022年には、病院薬局が最大の市場シェアを占めました。
国別に見ると、中東およびアフリカの感染症治療薬市場は、サウジアラビア、南アフリカ、UAE、その他の中東およびアフリカに分類されています。 2022年、中東およびアフリカの感染症治療薬市場シェアはサウジアラビアが独占しました。
中東およびアフリカの感染症治療薬市場で事業を展開している大手企業には、AbbVie Inc、Astellas Pharma Inc、Bayer AG、F. Hoffmann-La Roche Ltd、Gilead Sciences Inc、GSK Plc、Merck & Co Inc、Pfizer Incなどがあります。
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Middle East & Africa Infectious Disease Therapeutics Market - Key Market Dynamics
4.1 Middle East & Africa Infectious Disease Therapeutics Market - Key Market Dynamics
4.2 Market Drivers
4.2.1 Rising Prevalence of Infectious Disease
4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics
4.3 Market Restraints
4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects
4.4 Market Opportunities
4.4.1 Escalating Threat of Antibiotic Resistance
4.5 Future Trends
4.5.1 Rising Number of Product Approvals and Launches
4.6 Impact of Drivers and Restraints:
5. Infectious Disease Therapeutics Market - Middle East & Africa Market Analysis
5.1 Middle East & Africa Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
6. Middle East & Africa Infectious Disease Therapeutics Market Analysis - by Drug Class
6.1 Overview
6.2 Anti-Viral
6.2.1 Overview
6.2.2 Anti-viral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Anti-bacterial
6.3.1 Overview
6.3.2 Anti-bacterial: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Anti-fungal
6.4.1 Overview
6.4.2 Anti-fungal: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Others
6.5.1 Overview
6.5.2 Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7. Middle East & Africa Infectious Disease Therapeutics Market Analysis - by Indication
7.1 Overview
7.2 HIV
7.2.1 Overview
7.2.2 HIV: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Hepatitis
7.3.1 Overview
7.3.2 Hepatitis: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Tuberculosis
7.4.1 Overview
7.4.2 Tuberculosis: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Influenza
7.5.1 Overview
7.5.2 Influenza: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.6 HPV
7.6.1 Overview
7.6.2 HPV: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8. Middle East & Africa Infectious Disease Therapeutics Market Analysis - by Route of Administration
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Topical
8.4.1 Overview
8.4.2 Topical: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9. Middle East & Africa Infectious Disease Therapeutics Market Analysis - by Distribution Channel
9.1 Overview
9.2 Hospital Pharmacies
9.2.1 Overview
9.2.2 Hospital Pharmacies: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Retail Pharmacies
9.3.1 Overview
9.3.2 Retail Pharmacies: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10. Middle East & Africa Infectious Disease Therapeutics Market - Country Analysis
10.1 Middle East & Africa Infectious Disease Therapeutics Market
10.1.1 Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
10.1.1.1 Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
10.1.1.2 South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 Overview
10.1.1.3 Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 Saudi Arabia: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.3.2 Saudi Arabia: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.3.3 Saudi Arabia: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.3.4 Saudi Arabia: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.4 South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.1 Overview
10.1.1.5 South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.1 South Africa: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.5.2 South Africa: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.5.3 South Africa: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.5.4 South Africa: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.6 United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.1 Overview
10.1.1.7 United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.7.1 United Arab Emirates: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.7.2 United Arab Emirates: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.7.3 United Arab Emirates: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.7.4 United Arab Emirates: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.8 Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.8.1 Overview
10.1.1.9 Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.9.1 Rest of Middle East & Africa: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.9.2 Rest of Middle East & Africa: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.9.3 Rest of Middle East & Africa: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.9.4 Rest of Middle East & Africa: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
11. Infectious Disease Therapeutics Market-Industry Landscape
11.1 Overview
11.2 Growth Strategies in the Infectious Disease Therapeutics Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Pfizer Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Gilead Sciences Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 F. Hoffmann-La Roche Ltd
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Bayer AG
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 GSK Plc
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 AbbVie Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Merck & Co Inc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Astellas Pharma Inc
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
13. Appendix
13.1 About The Insight Partners
List of Tables
Table 1. Middle East & Africa Infectious Disease Therapeutics Market Segmentation
Table 2. Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Drug Class
Table 3. Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication
Table 4. Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 5. Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 6. Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Country
Table 7. Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 8. Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 9. Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 10. Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 11. South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 12. South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 13. South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 14. South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 15. United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 16. United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 17. United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 18. United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 19. Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 20. Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication
Table 21. Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 22. Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 23. Recent Inorganic Growth Strategies in the Infectious Disease Therapeutics Market
Table 24. Recent Organic Growth Strategies in the Infectious Disease Therapeutics Market
List of Figures
Figure 1. Middle East & Africa Infectious Disease Therapeutics Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. Middle East & Africa Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
Figure 4. Middle East & Africa Infectious Disease Therapeutics Market Share (%) - by Drug Class (2022 and 2030)
Figure 5. Anti-viral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 6. Anti-bacterial: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Anti-fungal: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Middle East & Africa Infectious Disease Therapeutics Market Share (%) - by Indication (2022 and 2030)
Figure 10. HIV: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hepatitis: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Tuberculosis: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Influenza: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. HPV: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Middle East & Africa Infectious Disease Therapeutics Market Share (%) - by Route Of Administration (2022 and 2030)
Figure 17. Oral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Parenteral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Topical: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Middle East & Africa Infectious Disease Therapeutics Market Share (%) - by Distribution Channel (2022 and 2030)
Figure 22. Hospital Pharmacies: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Retail Pharmacies: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. Middle East & Africa Infectious Disease Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
Figure 26. Middle East & Africa Infectious Disease Therapeutics Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 27. Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 28. South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 29. United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 30. Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 31. Growth Strategies in the Infectious Disease Therapeutics Market
1. AbbVie Inc
2. Astellas Pharma Inc
3. Bayer AG
4. F. Hoffmann-La Roche Ltd
5. Gilead Sciences Inc
6. GSK Plc
7. Merck & Co Inc
8. Pfizer Inc
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa infectious disease therapeutics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa infectious disease therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the Middle East & Africa infectious disease therapeutics market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.